COMBIMATRIX TO LAUNCH NON-INVASIVE CANCER SCREENING TEST.CombiMatrix Corporation (Nasdaq:CBMX) Mukilteo, Wash., has announced positive preliminary data on its investigational Comprehensive Cancer Array (CCA (1) (Common Cryptographic Architecture) Cryptography software from IBM for MVS and DOS applications.
(2) (Compatible Communications A ) test showing it can non- invasively screen for the early detection of cancer. The study focused on prostate, colon, ovarian ovarian /ovar·i·an/ (o-var´e-an) pertaining to an ovary or ovaries.
pertaining to an ovary.
ovarian agenesis , breast, and lung cancers, as these five cancers comprise roughly 85% of all solid tumors in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. .
Preliminary data using serum from cancer-free patients and patients with cancer at various stages (stage 1 to stage 4) were presented. CombiMatrix used a comprehensive micro RNA RNA: see nucleic acid.
in full ribonucleic acid
One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic (miRNA, a recently discovered type of nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. ) array built on its CustomArray(tm) platform to perform this study. The study's key demonstration was that the miRNA expression patterns, in blood, for patients with cancer (including early stage 1) were dramatically different from patients who were cancer-free. The resulting analysis indicated that a clear distinction could be made between patients with cancer and those without. Results also indicated that identification of the specific cancer was possible. Further data from this and other studies will be presented in the coming months.
"We are very pleased with the initial results of our Comprehensive Cancer Screening test. Early detection is the key to improving survival in cancer patients, and we believe that our non-invasive, blood-based screening test could revolutionize the way cancer is diagnosed and treated." said Dr. Amit Kumar, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombiMatrix. "This test has the potential to provide tremendous benefits to patients as well as significant cost savings in the healthcare system."
While early detection and treatment is proven to improve survival for cancer patients, there are no non-invasive, blood-based early screening tests except for those used in prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . As a result, patients tend to delay screening tests such as colonoscopies due to their invasive nature, which reduces the likelihood that such cancers will be detected and treated early.
"We believe there is significant market potential for this test," Dr. Kumar, continued. "Candidates for this test include all individuals over 40, those with a history of cancer in the family, as well as those who have been tested to have a high genetic risk of contracting cancer (for example those who are positive using Myriad Genetic's (NASDAQ:MYGN) BRACAnalysis(r) test for breast cancer risk)."
It is anticipated that the test will be ordered annually for patients in the noted categories, or perhaps more frequently. The test is non-invasive, requiring only a blood sample from the patient. The CCA is not designed to identify those who might be at high risk of cancer. The goal of this test is to identify existing cancerous or pre-cancerous growths in individuals at the time of the test and furthermore, to identify the organ system where the growth might be. CombiMatrix hopes to launch the test in 2010 and believes the market opportunity for this single test is in the range of several billion dollars annually in the U.S. alone.
The study, titled "Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray," was presented as a poster by Dr. Dominic Suciu, Senior Scientist at CombiMatrix. The poster can be viewed at http://investor.combimatrix.com/miRNAPoster.cfm.
BRACAnalysis(r) is a registered trademark of Myriad Genetics Myriad Genetics is a leading biopharmaceutical company focused on understanding the relationship between genes, proteins and human diseases in order to develop the next generation of therapeutic and molecular diagnostic products. , Inc.
ABOUT COMBIMATRIX CORPORATION
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security Noun 1. Homeland Security - the federal department that administers all matters relating to homeland security
Department of Homeland Security
executive department - a federal department in the executive branch of the government of the United States markets, as well as in other potential markets where our products and services could be utilized. The technologies they have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry Combinatorial chemistry involves the rapid synthesis or the computer simulation of a large number of different but structurally related molecules. Introduction
Synthesis of molecules in a combinatorial fashion can quickly lead to large numbers of molecules. , material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. ("CMDX"), a wholly owned subsidiary Wholly Owned Subsidiary
A subsidiary whose parent company owns 100% of its common stock.
In other words, the parent company owns the company outright and there are no minority owners. located in Irvine, California Irvine is an incorporated city in Orange County, California, United States. It is a planned city, mainly developed by the Irvine Company since the 1960s. Formally incorporated on December 28 1971, the 69.7 square mile (180.5 km²) city has a population of 202,079 (as of 2007). , has developed capabilities of producing arrays that utilize bacterial artificial chromosomes A bacterial artificial chromosome (BAC) is a DNA construct, based on a fertility plasmid (or F-plasmid), used for transforming and cloning in bacteria, usually E. coli. , which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory.
For more information about CombiMatrix Corporation is available at http://www.combimatrix.com or by call 1-800-985 CBMX (2269) or visit http://www.cmdiagnostics.com or call 1-800-710-0624.